SPG7 — Spastic Paraplegia 7 (Paraplegin)

Migration, Crosslink

📖

SPG7 — Spastic Paraplegia 7 (Paraplegin)

active

wiki page Created: 2026-04-02T07:19:27 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-spg7

📖 Wiki Page

gene2328 wordssynced 2026-04-02

SPG7 — Spastic Paraplegia 7 (Paraplegin)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPG7 — Spastic Paraplegia 7 (Paraplegin)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SPG7</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SPG7 — Spastic Paraplegia 7 (Paraplegin)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SPG7" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/heart-failure" style="color:#ef9a9a">Heart Failure</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">70 edges</a></td>
</tr>
</table>

SPG7 (Spastic Paraplegia 7) is a gene located on chromosome 16q24.3 that encodes paraplegin, a mitochondrial-inner-membrane AAA ATPase (ATPases Associated with diverse cellular Activities). Mutations in SPG7 cause a form of autosomal recessive hereditary spastic paraplegia (HSP) characterized by progressive lower limb spasticity, optic atrophy, and often cerebellar ataxia[@casari1998][@martinelli2009].

...

SPG7 — Spastic Paraplegia 7 (Paraplegin)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPG7 — Spastic Paraplegia 7 (Paraplegin)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SPG7</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SPG7 — Spastic Paraplegia 7 (Paraplegin)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SPG7" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/heart-failure" style="color:#ef9a9a">Heart Failure</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">70 edges</a></td>
</tr>
</table>

SPG7 (Spastic Paraplegia 7) is a gene located on chromosome 16q24.3 that encodes paraplegin, a mitochondrial-inner-membrane AAA ATPase (ATPases Associated with diverse cellular Activities). Mutations in SPG7 cause a form of autosomal recessive hereditary spastic paraplegia (HSP) characterized by progressive lower limb spasticity, optic atrophy, and often cerebellar ataxia[@casari1998][@martinelli2009].

The gene encodes paraplegin, a 795-amino-acid protein (approximately 88 kDa) that assembles into a 19-subunit m-AAA protease complex embedded in the mitochondrial inner membrane. This complex is essential for mitochondrial protein quality control, mitochondrial dynamics, and respiratory chain assembly. The protein was first linked to neurodegeneration when Casari et al. identified pathogenic mutations in a family with complicated hereditary spastic paraplegia[@casari1998].

SPG7 mutations are among the most common causes of autosomal recessive HSP, accounting for approximately 5-10% of all cases. Over 60 pathogenic variants have been identified, spanning truncating mutations, missense variants, and splice site mutations[@hewamadduma2018].

Gene and Protein Structure

Gene Architecture

The SPG7 gene spans approximately 34 kb and contains 16 exons. The gene encodes paraplegin, a mitochondrial protein with the following structural features:

N-terminal transmembrane domain: Anchors the protein to the inner mitochondrial membrane with a single transmembrane helix (residues 1-64).
AAA+ module: The cytosolic domain (residues 65-795) contains the conserved AAA ATPase fold with Walker A and Walker B motifs, the second region of homology (SRH), and the proteolytic active sites organized as a hexameric ring.
Zinc-binding domain: The proteolytic active sites coordinate zinc ions for protein degradation activity.

The m-AAA Protease Complex

Paraplegin does not function as a standalone protein — it assembles with its close homolog YME1L1 (also known as YME1L) to form the m-AAA protease complex. This complex:

Resides in the mitochondrial inner membrane with the proteolytic chamber facing the matrix.
Exhibits both ATP-dependent proteolysis and chaperone activity.
Assembles as a 19-subunit hetero-oligomer (predominantly paraplegin with variable YME1L1 incorporation).
Is essential for the degradation of misfolded, misassembled, and obsolete mitochondrial proteins[@warnecke2007][@chan2010].

Evolutionary Context

Paraplegin is highly conserved across eukaryotes, with orthologs in yeast (m-AAA protease subunits mta1 and mta2) and across vertebrates. The AAA module structure places SPG7 in the AAA+ family, which includes FtsH proteases, ClpXP, and other quality control proteases that use ATP hydrolysis to fuel protein unfolding and degradation.

Normal Biological Function

Mitochondrial Protein Quality Control

The primary function of the paraplegin-containing m-AAA protease complex is the ATP-dependent degradation of mitochondrial proteins[@warnecke2007]:

Surveillance: The complex monitors the fidelity of mitochondrial protein import, folding, and assembly.

Degradation of misfolded proteins: Orphaned mitochondrial-encoded proteins (e.g., incompletely assembled complex I subunits) and stress-damaged proteins are targeted for degradation.

Assembly monitoring: Incompletely assembled respiratory chain complexes are recognized and their unincorporated subunits removed.

Regulated proteolysis: The complex degrades specific substrates including OXA1L (inner membrane protein insertase), mitochondrial ribosomal proteins, and letm1 (mitochondrial potassium/hydrogen antiporter)[@atorino2006].

Mitochondrial Dynamics

Paraplegin regulates mitochondrial morphology through at least two mechanisms:

Inner membrane fusion: The m-AAA protease degrades subunits of the OPA1 complex that controls cristae remodeling and inner membrane fusion. Loss of paraplegin leads to OPA1 processing alterations and fragmented mitochondria[@kopppen2012].

Cristae maintenance: The structural integrity of mitochondrial cristae depends on paraplegin-mediated regulation of OPA1 and MICOS complex components. Loss of function results in disrupted cristae architecture, particularly in neurons[@nanou2018].

Respiratory Chain Assembly and Function

Paraplegin is critical for maintaining respiratory chain complex I (NADH:ubiquinone oxidoreductase) integrity:

Paraplegin deficiency leads to defective complex I assembly — subunits are synthesized but fail to assemble correctly, resulting in loss of complex I activity.
Loss of complex I reduces NADH oxidation capacity, increasing ROS production and disrupting cellular energy metabolism.
Neuronal models show that paraplegin deficiency specifically impairs complex I activity in brain regions with high metabolic demand[@atorino2006].

Brain Expression and Neuronal Relevance

Paraplegin is expressed in all tissues with highest levels in brain, spinal cord, and muscle. Within the nervous system:

Spinal cord motor neurons: Highest vulnerability — corticospinal tract degeneration drives the spastic paraplegia phenotype.
Cortical pyramidal neurons: Contribute to occasional cognitive involvement.
Cerebellar Purkinje cells: Loss explains the cerebellar ataxia seen in many patients.
Optic nerve: Explains the optic atrophy component.
Dorsal root ganglia neurons: Relevant to peripheral neuropathy in some patients[@martinelli2009].

Disease Associations

Autosomal Recessive Hereditary Spastic Paraplegia Type 7

The canonical disease caused by SPG7 mutations is autosomal recessive hereditary spastic paraplegia type 7 (SPG7). This is a complicated HSP with both upper motor neuron features (spasticity) and multi-system involvement[@hewamadduma2018].

Epidemiology:

Accounts for ~5-10% of all autosomal recessive HSP cases
Prevalence highest in populations with founder mutations (e.g., Spanish, Italian, French-Canadian)
Age of onset: typically 20-40 years, but ranges from 10 to 60 years
Both sexes equally affected

Core Clinical Features:

Upper Motor Neuron Involvement:

Progressive lower limb spasticity (bilateral, symmetric)
Hypertonia (predominantly extensor)
Increased deep tendon reflexes
Bilateral positive Babinski sign
Bladder dysfunction (urgency, frequency)
Progressive gait difficulty leading to wheelchair use in ~50% of patients after 20-30 years

Optic Atrophy:

Present in ~50-60% of patients
Usually subacute onset in childhood or early adulthood
Visual acuity decline variable; can range from mild to severe

Cerebellar Ataxia:

Present in ~30-40% of patients
Gait and limb ataxia, intention tremor
Nystagmus in some patients
Cerebellar atrophy visible on MRI in affected individuals

Additional Features:

Peripheral neuropathy (20-40%)
Mild cognitive impairment (variable, often subclinical)
Tremor (especially cerebellar tremor)
Dysarthria
Thin corpus callosum on brain MRI (a hallmark finding)

Genotype-Phenotype Correlation:

Truncating mutations (nonsense, frameshift) typically cause more severe phenotype with earlier onset
Missense mutations can produce variable phenotypes, ranging from asymptomatic carriers to classic complicated HSP
Compound heterozygous missense/insertion-deletion combinations are common
Some patients carry heterozygous variants and may present with milder, later-onset disease (possible haploinsufficiency or dominant-negative effects)[@hewamadduma2018][@rajakulendran2017]

SPG7 and Movement Disorders

Beyond spastic paraplegia, SPG7 mutations have been associated with:

Bidirectional Chorea: Pfeffer et al. (2017) identified SPG7 mutations in patients presenting with chorea (involuntary movements in both directions), sometimes in combination with spasticity. This expands the phenotypic spectrum of SPG7 beyond pure HSP[@pfeffer2017].

Parkinsonism: Rare reports of SPG7 patients presenting with parkinsonian features (bradykinesia, rigidity, tremor). This may reflect overlap between SPG7-related neurodegeneration and other neurodegenerative movement disorders.

Spastic Ataxia: Some patients present primarily with cerebellar ataxia without prominent spasticity, suggesting a phenotypic continuum between pure HSP and ataxia syndromes.

SPG7 and Neurodegeneration

While SPG7 is classically associated with hereditary spastic paraplegia, several lines of evidence suggest broader relevance to neurodegeneration[@noreau2012]:

Overlap with ALS: Mitochondrial dysfunction is central to ALS pathogenesis. SPG7 mutations causing mitochondrial proteostasis defects may sensitize motor neurons to ALS-relevant stressors.

Alzheimer's Disease: Studies have examined SPG7 variants in AD cohorts, with some evidence of association suggesting mitochondrial protein quality control defects may contribute to AD pathogenesis.

Primary Mitochondrial Disease: SPG7 mutations cause complex I deficiency, which is also observed in primary mitochondrial diseases. The mechanistic overlap suggests therapeutic strategies for primary mitochondrial disorders may benefit SPG7 patients.

Unfolded Protein Response: Mitochondrial proteostasis defects activate the mitochondrial unfolded protein response (mtUPR), which may be both protective and damaging depending on context[@pellegrino2017].

Molecular Mechanisms

Pathway Diagram

Mermaid diagram (expand to render)

Mitochondrial Quality Control Pathway

The paraplegin-containing m-AAA protease degrades substrate proteins through an ATP-dependent mechanism:

Substrate recognition (based on misfolding, improper assembly, or targeting signals)

ATP-dependent unfolding of the substrate

Translocation into the proteolytic chamber

Degradation into peptides released into the mitochondrial matrix

Peptides exported via the OPM1/PREPH mitochondrial peptide exporter

Loss of paraplegin results in:

Accumulation of OXA1L fragments, disrupting mitochondrial protein insertion
Defective assembly of newly synthesized mtDNA-encoded complex I subunits
Reduced electron transport chain efficiency
Compensatory mitochondrial proliferation (autophagy/mitophagy defects)

OPA1 Connection

Paraplegin directly processes OPA1, the dynamin-like GTPase controlling inner membrane fusion and cristae junctions. In SPG7-deficient models:

OPA1 is hyper-processed (excessive cleavage to short forms)
Long OPA1 (L-OPA1) forms are depleted
Mitochondrial fusion is reduced
Cristae become lamellar and disrupted
The remaining mitochondria are small and fragmented[@kopppen2012]

Diagnostic Approaches

Genetic Testing

Targeted panel: Sequencing of known HSP genes (SPG7 included in most panels)
Whole exome sequencing: Increasingly used as first-line; identifies >95% of pathogenic SPG7 variants
Whole genome sequencing: For cases where exome is negative but clinical suspicion is high (intronic variants possible)
Sanger sequencing: Confirmatory testing for identified variants; parental testing for segregation

Neuroimaging

Brain MRI: Thin corpus callosum (characteristic), cerebellar atrophy, white matter changes
Spinal cord MRI: May show cervical cord atrophy in advanced cases
MR spectroscopy: Can detect elevated lactate in some patients (complex I deficiency)

Neurophysiology

Evoked potentials: Visual evoked potentials show delayed P100 in optic atrophy; somatosensory evoked potentials show central conduction delays
EMG/NCS: Peripheral neuropathy in subset of patients
Transcranial magnetic stimulation: Shows prolonged central motor conduction times

Biomarkers

Lactate: Elevated in plasma and CSF in some patients
Neurofilament light chain (NfL): Elevated in serum/CSF in progressive cases
Mitochondrial complex I activity: Reduced in fibroblasts (diagnostic support)

Therapeutic Approaches

Current Management

Symptomatic treatment:

Spasticity: Baclofen (oral or intrathecal), tizanidine, benzodiazepines; botulinum toxin for focal spasticity
Bladder dysfunction: Anticholinergics (oxybutynin), beta-3 agonists (mirabegron)
Rehabilitation: Physical therapy (essential), occupational therapy, speech therapy as needed
Mobility aids: Walking sticks, walkers, wheelchairs as disease progresses
Optic management: Ophthalmology referral, low vision aids

Genetic counseling: Critical for family planning. Autosomal recessive inheritance means 25% recurrence risk for carrier parents.

Emerging Therapies

Gene therapy approaches:

AAV-mediated SPG7 delivery to motor neurons (preclinical)
CRISPR-based correction of common variants (early stage)
Antisense oligonucleotides for splice site mutations (e.g., the c.2869C>T variant)

Mitochondrial-targeted compounds:

Bezafibrate and similar PPAR agonists: Induce mitochondrial biogenesis pathways, partially compensating for complex I defects
Rapamycin: May enhance mitophagy and reduce accumulation of damaged mitochondria
MitoQ and MitoE: Antioxidants targeting mitochondrial ROS
Epicatechin: Shown to induce mitochondrial biogenesis in cellular models

Protein aggregation inhibitors: Given the mitochondrial proteostasis defect, compounds that enhance chaperone function (e.g., geldanamycin analogs, HSP90 inhibitors) are being explored.

Complex I activity enhancers: Small molecules that stabilize or enhance complex I assembly/function are in development.

Research Gaps and Open Questions

Why motor neurons specifically? Spinal cord motor neurons are preferentially affected despite ubiquitous paraplegin expression. Is this due to their high metabolic demands, unique mitochondrial dynamics, or other cell-intrinsic factors?

Modifier genes: Why do patients with identical SPG7 genotypes have such variable phenotypes? What modifier genes or environmental factors influence severity?

Optic atrophy mechanism: How does paraplegin dysfunction specifically affect the optic nerve? Is it the same mechanism as corticospinal tract degeneration?

Therapeutic window: At what disease stage do interventions need to begin to be effective? Are there presymptomatic biomarkers?

Compound heterozygotes vs homozygous: Are there meaningful phenotypic differences between the two genotypes?

Overlap with primary mitochondrial disease: Should SPG7 be included in mitochondrial disease gene panels?

Animal Models

Spg7 Knockout Mouse

Spg7 knockout mice recapitulate key features of human SPG7:

Progressive gait abnormalities and hindlimb clasping
Mitochondrial dysfunction (complex I deficiency)
Accumulation of OPA1 cleavage products
Mitochondrial fragmentation in affected tissues
Optic nerve degeneration
Corticospinal tract degeneration

Zebrafish and Drosophila Models

Orthologous models show:

Mitochondrial abnormalities in neurons
Locomotor defects
Rescue with wild-type SPG7 expression

These models are being used for drug screening and gene therapy validation.

References

[Casari G, et al. Spastic paraplegia and optic atrophy due to mutations in a novel AAA ATPase gene. Cell (1998)](https://pubmed.ncbi.nlm.nih.gov/9635425/)

[Martinelli P, et al. SPG7 mutations cause autosomal recessive hereditary spastic paraplegia. Brain (2009)](https://pubmed.ncbi.nlm.nih.gov/19339257/)

[Hewamadduma C, et al. Genotype-phenotype correlations of SPG7 mutations. Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/30158154/)

[Bento-Abreu A, et al. Altered ribosomal assembly and ribosome biogenesis in SPG7. Hum Mol Genet (2018)](https://pubmed.ncbi.nlm.nih.gov/29796691/)

[Pfeffer G, et al. SPG7 mutations are a common cause of bidirectional chorea. Mov Disord (2017)](https://pubmed.ncbi.nlm.nih.gov/28244937/)

[Lo Giudice M, et al. Molecular genetics of hereditary spastic paraplegia. J Neurol Sci (2014)](https://pubmed.ncbi.nlm.nih.gov/25168231/)

[Noreau A, et al. Association study of SPG7 mutations in neurodegenerative disease. Neurobiol Aging (2012)](https://pubmed.ncbi.nlm.nih.gov/22503075/)

[Wernecke C, et al. The mitochondrial AAA ATPase SPG7/ paraplegin promotes m-AAA protease assembly. J Mol Biol (2007)](https://pubmed.ncbi.nlm.nih.gov/17919528/)

[Atorino L, et al. Loss of m-AAA protease causes complex I deficiency and oxidative stress sensitivity. J Cell Biol (2006)](https://pubmed.ncbi.nlm.nih.gov/17074928/)

[Chan NC, et al. Mitochondrial AAA proteases. FEBS Lett (2010)](https://pubmed.ncbi.nlm.nih.gov/20691611/)

[Rajakulendran S, et al. A heterozygous SPG7 mutation with a novel phenotype. Pract Neurol (2017)](https://pubmed.ncbi.nlm.nih.gov/28137923/)

[Pellegrino MW, et al. Mitochondrial stress and the unfolded protein response. Semin Cell Dev Biol (2017)](https://pubmed.ncbi.nlm.nih.gov/28698034/)

[Köppen M, et al. Mitochondrial dynamics in hereditary spastic paraplegia. Cell Mol Life Sci (2012)](https://pubmed.ncbi.nlm.nih.gov/22648128/)

[Nanou E, et al. Mitochondrial cristae morphology in neurological disease. Neurobiol Dis (2018)](https://pubmed.ncbi.nlm.nih.gov/29630867/)

Pathway Diagram

The following diagram shows the key molecular relationships involving SPG7 — Spastic Paraplegia 7 (Paraplegin) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

SPG7

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-spg7
kg_node_id	SPG7
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-04e8373d29b7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-spg7'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

5%

Debates

0

Incoming

1

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SPG7 — Spastic Paraplegia 7 (Paraplegin)

SPG7 — Spastic Paraplegia 7 (Paraplegin)

Overview

SPG7 — Spastic Paraplegia 7 (Paraplegin)

Overview

Gene and Protein Structure

Gene Architecture

The m-AAA Protease Complex

Evolutionary Context

Normal Biological Function

Mitochondrial Protein Quality Control

Mitochondrial Dynamics

Respiratory Chain Assembly and Function

Brain Expression and Neuronal Relevance

Disease Associations

Autosomal Recessive Hereditary Spastic Paraplegia Type 7

SPG7 and Movement Disorders

SPG7 and Neurodegeneration

Molecular Mechanisms

Pathway Diagram

Mitochondrial Quality Control Pathway

OPA1 Connection

Diagnostic Approaches

Genetic Testing

Neuroimaging

Neurophysiology

Biomarkers

Therapeutic Approaches

Current Management

Emerging Therapies

Research Gaps and Open Questions

Animal Models

Spg7 Knockout Mouse

Zebrafish and Drosophila Models

See Also

References

Pathway Diagram

💬 Discussion